LY3484356 in participants with advanced or metastatic breast cancer - Clinical trial • Breast Cancer Foundation NZ

Donate to save lives this Breast Cancer Awareness Month.

LY3484356 in participants with advanced or metastatic breast cancer

Advanced Breast Cancer clinical trials for ER+

Recruiting
Updated: July 6, 2020

This study will see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer.

The reason for this study is to see if the study drug LY3484356 alone or in combination with abemaciclib is safe and effective in participants with advanced or metastatic breast cancer.

Who is it for?

You may be eligible for this study if you meet the below criteria:

  • Participants with ER+, HER2- breast cancer that may have spread to other part(s) of the body and has had up to three lines of standard therapy and progression while on endocrine-containing therapy for ≥24 months in the adjuvant setting or ≥6 months in advanced/metastatic setting
  • Participants must be willing to provide adequate archival tissue sample
  • Participants must be willing to use highly effective birth control
  • Participants must have adequate organ function
  • Participants must be able to swallow capsules

Study details

Participants will be given either LY3484356 or LY3484356 with abemaciclib orally. Dosages will be escalated or expanded as the study goes on.

For full trial information

Australia

St Vincent's Hospital, Darlinghurst

If you think you might be a candidate for this trial, use the contact details supplied, or talk to your doctor.

Want to access a trial that's not in your area? It's not always possible, but if you're interested, email us at intouch@bcf.org.nz

Similar clinical trials

For Advanced Breast Cancer

Are we out of date? If you have updated or new information about a trial, we’d be grateful if you’d share it with us – email your update to intouch@bcf.org.nz

Find clinical trials

Interested in a clinical trial?

Subscribe for updates & stay in the loop with new studies.